Keywords: antisoma, regains, r1550, roche, moves, ph, iia

Antisoma regains R1550 from Roche, moves to Ph IIa

Article | 26 June 2006

Print This

UK cancer specialist Antisoma has completed a Phase I trial of its drug candidate R1550 (huHMFG1) and presented the results ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in